{"id":13832,"date":"2026-05-22T12:49:42","date_gmt":"2026-05-22T11:49:42","guid":{"rendered":"https:\/\/www.thervacb.eu\/?p=13832"},"modified":"2026-05-22T12:49:42","modified_gmt":"2026-05-22T11:49:42","slug":"early-trial-results-support-ongoing-thervacb-hepatitis-b-patient-study","status":"publish","type":"post","link":"https:\/\/www.thervacb.eu\/de\/early-trial-results-support-ongoing-thervacb-hepatitis-b-patient-study\/","title":{"rendered":"Early trial results support ongoing TherVacB hepatitis B patient study"},"content":{"rendered":"

[et_pb_section fb_built=“1″ _builder_version=“4.16″ da_disable_devices=“off|off|off“ global_colors_info=“{}“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row _builder_version=“4.16″ background_size=“initial“ background_position=“top_left“ background_repeat=“repeat“ custom_padding=“||0px|||“ global_colors_info=“{}“][et_pb_column type=“4_4″ _builder_version=“4.16″ custom_padding=“|||“ global_colors_info=“{}“ custom_padding__hover=“|||“][et_pb_text _builder_version=“4.25.0″ background_size=“initial“ background_position=“top_left“ background_repeat=“repeat“ min_height=“407px“ hover_enabled=“0″ global_colors_info=“{}“ sticky_enabled=“0″]<\/p>\n

May 2026
<\/b>Scientific Results | Clinical Development | Hepatitis B Research<\/span><\/p>\n

New early clinical trial results support the ongoing TherVacB patient study for chronic hepatitis B.<\/h2>\n

A recent analysis published by GlobalData Healthcare<\/em> and Clinical Trials Arena<\/em> highlights findings from a completed first-in-human Phase Ia clinical study conducted outside the EU-funded TherVacB project.<\/p>\n

In healthy adult volunteers, the therapeutic vaccine candidate \u201cTherVacB\u201d was shown to be safe, well tolerated, and capable of triggering strong immune responses. Early studies of this kind are an essential first step before evaluating new therapeutic approaches in people living with chronic hepatitis B.<\/p>\n

These results provide important support for the ongoing TherVacB clinical study, which aims to develop a functional cure for chronic hepatitis B by helping the immune system regain control over HBV infection.<\/p>\n

Why do these early results matter for TherVacB patients?<\/strong><\/p>\n

Chronic hepatitis B affects around 254 million people worldwide and can lead to liver cirrhosis and liver cancer. Current treatments can suppress the virus, but they rarely achieve a functional cure and often require lifelong therapy.<\/p>\n

The TherVacB EU project is developing a therapeutic vaccine approach designed to help the immune system regain long-term control over HBV infection.<\/p>\n

The completed Phase Ia is important because it showed for the first time that the \u201cTherVacB\u201d vaccine candidate could safely trigger strong immune responses in humans. These findings provide important support for the ongoing TherVacB patient study and the project\u2019s continued clinical development pathway.<\/p>\n

What happens next in the TherVacB patient study?<\/strong><\/p>\n

TherVacB clinical centres are actively enrolling people living with chronic hepatitis B into the ongoing Phase Ib patient study.<\/p>\n

This study is an important next step in evaluating the TherVacB vaccine approach in people affected by chronic HBV infection. The encouraging findings from healthy volunteers are now helping guide the ongoing patient study. Researchers are now assessing safety, tolerability, and immune responses to better understand whether the vaccine approach can help patients regain immune control over the virus.<\/p>\n

Alongside the clinical study, the TherVacB project continues its work on immune monitoring, biomarker research, patient engagement, and awareness activities to support the long-term goal of developing a functional cure for chronic hepatitis B.<\/p>\n

Read More<\/strong><\/p>\n